RET and cancer: BRAFV600E and RET mutations and RET fusions have high PPV for malignancy, can be found in aggressive thyroid cancers, and are rarely if ever found in benign adenomas or hyperplastic nodules.10, 11, 12BRAF‐related fusion transcripts have also been associated with BRAFV600E‐like properties, although they are more commonly found in pediatric thyroid cancer populations11, 13, 14, 15TERT promoter mutations have been strongly correlated to persistent disease, aggressive forms of cancer, distant metastasis, and mortality.16, 17, 18, 19, 20, 21